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BASIC RESEARCH STUDIES
HIV Tat protein causes endothelial dysfunction in
porcine coronary arteries
Ramesh Paladugu, MD, Weiping Fu, MD, Brian S. Conklin, PhD, Peter H. Lin, MD, Alan B. Lumsden,
MD, Qizhi Yao, MD, PhD, and Changyi Chen, MD, PhD, Houston, Tex
Purpose: Human immune deficiency virus (HIV) infection is often associated with chronic diseases, including atheroscle-
rosis. However, the molecular mechanisms are largely unknown. We examined the effect of Tat protein, an HIV
regulatory protein, on endothelial function in porcine coronary arteries.
Methods: Porcine coronary arteries were dissected from nine pig hearts and cut into 5-mm ring segments, which were
incubated as controls or with Tat protein (107, 109, 1011 mol/L) or Tat protein plus anti-Tat antibody, for 24 hours.
Myography was performed with thromboxane A2 analog U46619 (10 7 mol/L) for contraction and with graded doses
of bradykinin (108, 107, and 106 mol/L) or sodium nitroprusside (105 mol/L) for relaxation. Endothelial nitric
oxide synthase (eNOS) messenger RNA was determined with reverse transcriptase polymerase chain reaction (RT-PCR),
and protein levels were determined with Western blot analysis. Immunoreactivity of eNOS of treated rings was also
detected.
Results: Endothelium-dependent vasorelaxation (107 mol/L of bradykinin) was significantly reduced (46.41%) in pig
coronary artery rings treated with 107 mol/L of Tat protein, as compared with control arteries (P < .05). Arteries
treated with Tat protein plus anti-Tat antibody relaxed similarly as control arteries. There were no differences in smooth
muscle contractility (U46619) or endothelium-independent vasorelaxation (sodium nitroprusside) between control and
Tat protein–treated groups. RT-PCR for eNOS mRNA showed reduction in eNOS levels for Tat-treated coronary artery
rings by 73%, as compared with control vessels (P < .05). Tat protein–treated vessels demonstrated substantially less
eNOS protein band intensity and immunoreactivity compared with control vessels.
Conclusions: Tat protein significantly decreased endothelium-dependent vasorelaxation and eNOS mRNA and protein
expression in endothelial cells of porcine coronary arteries. This study suggests that Tat protein–mediated endothelial
dysfunction may be important in coronary heart disease in HIV-infected patients. (J Vasc Surg 2003;38:549-56.)
Patients with human immunodeficiency virus (HIV)
infection have an increased incidence of premature coro-
nary artery disease. Highly active antiretroviral therapy has
increased life expectancy of HIV-infected patients by de-
creasing HIV replication and its coincident deleterious
effects on the immune system. Development and rapid
progression of aggressive atherosclerotic lesions in young
patients with acquired immunodeficiency disease (AIDS)
without cardiovascular risk factors suggest that atheroscle-
rosis may be accelerated after HIV infection.1,2 Autopsy
reports were the first to describe an association between
coronary artery disease and HIV infection.3-5 Many clinical
and autopsy studies have suggested an increased incidence
of stroke in HIV-infected patients, including children and
young adults. Cerebral infarction has been reported in 4%
to 29% of patients with AIDS.6,7 These lesions may result
from cerebral artery aneurysm formation and atherosclero-
sis with occlusion. HIV infection may also cause endothe-
lial damage, and predispose to atherosclerotic disease
through its effect on triglyceride levels.8
Although extensive clinical investigations have indi-
cated accelerated atherosclerosis in patients with HIV, the
cellular and molecular mechanisms of HIV-mediated vas-
cular pathogenesis are not fully understood.9,10 Endothe-
lial injury or dysfunction could significantly contribute to
the pathogenesis of vascular disease in HIV-infected pa-
tients. HIV proteins may be important in vascular injury.
HIV-1 Tat protein is an early viral protein, with 101 amino
acids when isolated from primary HIV isolates or 86 amino
acids when isolated from the laboratory strain HBX2, and
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which still retains full activity.11 Tat is a nuclear regulatory
protein that is critical in HIV-1 replication.12,13 Tat can be
actively released from infected cells,14 and thus other cell
types can be exposed to elevated levels of this protein. Tat
enters uninfected cells via the circulation, and once inter-
nalized it alters cellular physiology by positively or nega-
tively affecting gene expression. For example, Tat activates
interleukin-8 secretion in human brain–derived endothelial
cells15 and E-selectin expression in human umbilical vein
endothelial cells.16 However, specific effects of Tat on
coronary endothelial cells have not yet been established.
We examined the effect of Tat protein on vasomotor func-
tion and endothelial nitric oxide synthase (eNOS) messen-
ger RNA expression in porcine coronary arteries. Immuno-
reactivity and protein expression of eNOS in treated vessels
were also studied. Our results could advance understanding
of the pathogenic mechanisms of Tat protein on vascular
endothelium.
METHODS
Chemicals and reagents. Recombinant HIV-1 Tat
protein and HIV-1 Tat antiserum were obtained from the
National Institutes of Health AIDS Research and Refer-
ence Reagent Program (Rockville, Md). Tat was dissolved
in phosphate-buffered saline solution (PBS). Thrombox-
ane A2 (TxA2) analog (9,11-dideoxy-11a, 9 a-epoxymeth-
anoprostaglandin F2a) (U46619), bradykinin, Tris-
buffered saline solution (TBS), PBS, and anti-human -
actin monoclonal antibody were obtained from Sigma (St
Louis, Mo). Dulbecco modified Eagle medium (DMEM)
was obtained from Life Technologies (Grand Island, NY),
antibiotic-antimycotic was obtained from Mediatech
(Herndon, Va), and the one-step reverse transcriptase poly-
merase chain reaction (RT-PCR) kit was obtained from
Promega (Madison, Wis). The protein assay kit and precast
polyacrylamide gels were obtained from Bio-Rad Labora-
tories (Hercules, Calif). Antibody against eNOS was from
BD Bioscience/Pharmingen (San Diego, Calif), and the
horseradish peroxidase–conjugated goat anti-mouse sec-
ondary antibody and enhanced chemiluminescence kit
were from Amersham life Sciences (Buckinghamshire, En-
gland). Avidin-biotin complex immunoperoxidase kit was
obtained from Dako (Carpenteria, Calif).
Isometric tension of porcine coronary arteries. The
myography system used in our laboratory has been de-
scribed.17 Nine pig hearts were harvested from farm pigs,
7 to 9 months old, at a local slaughterhouse. Animals were
killed by puncture wound to the aorta, and hearts were
harvested within 5 to 10 minutes after death. The hearts
were immediately rinsed with sterile PBS, and stored in ice
cold PBS for transport to the laboratory. Once in the
laboratory, the circumflex coronary artery was carefully
dissected from the heart. After loose connective tissue was
removed, the pig circumflex coronary artery was cut into
multiple 5-mm rings, which were then incubated in
DMEM with Tat protein (1011, 109, and 107 mol/L),
anti-Tat antibody plus Tat protein, or PBS (10 L) as
controls, at 37°C and 5% carbon dioxide in a cell culture
incubator for 24 hours. After culture, rings were suspended
between the wires of the organ bath myograph chamber
(Organ Bath 700MO; Danish MyoTechnology, Aarhus,
Denmark) in 6 mL of Krebs solution maintained at 37°C
and oxygenated with pure oxygen gas. Rings were sub-
jected stepwise to a predetermined optimal tension of 2.5g
and allowed to equilibrate for at least 45 minutes. After
equilibration, each ring was precontracted with TxA2 ana-
logue U46619 (107 mol/L). Subsequently the dose re-
sponse curves of vessel relaxation were generated with five
cumulative additions of the endothelium-dependent vaso-
dilator bradykinin (109, 108, 107, 106, 105 mol/L)
at 3-minute intervals. The drug volumes were not more
than 1% of the chamber volume, to reach the final concen-
tration required. Contractility and percentage of relaxation
were calculated on the basis of tension change. Data for
several coronary artery rings from each heart were averaged,
and represent one data point for statistical analysis.
RT-PCR. After myography, coronary artery rings
were removed from the system, the endothelial cells were
collected in 1.5 mL Eppendorf tubes in 1 mL of Tri-
Reagent (Sigma) solution by cutting the segments open
and scraping the endothelial surface with a No. 10 scalpel
and subsequently homogenizing the cells.18,19 Total RNA
of endothelial cells was isolated with Tri-Reagent according
to the manufacturer’s instructions. RNA from each vessel
ring was resuspended in 10 L of ribonuclease-free water,
and the concentration was determined with absorbance at
260 nm wavelength, with a spectrophotometer. A one-step
RT-PCR kit was used according to the manufacturer’s
instructions. Master tubes were used to reduce variability in
primer and reagent concentrations. Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), a housekeeping
gene, was used as internal control for eNOS expression, to
account for variations in RNA loading. The same total
RNA, 0.1 g, was loaded for all samples. Porcine eNOS
primer was 21 nucleotides long (sense, 5-GTGTTTGGC-
CGAGTCCTCACC-3; antisense, 5-CTCCTGCAAG-
GAAAAGCTCTG-3); porcine GAPDH primer was 25
nucleotides long (sense, 5-TGATGACATCAAGAAGGT-
GGTGAAG-3) and 23 nucleotides long (antisense, 5-
TCCTTGGAGGCCATGTGGACCAT-3).20 RT-PCR
was performed in a thermal cycler (Techne Ltd, Cam-
bridge, England), under the following conditions: 45 min-
utes at 48°C (reverse transcription), 2 minutes at 94°C
(denaturation), followed by PCR cycles of 94°C for 30
seconds (denaturation), 60°C for 60 seconds (annealing),
and 68°C for 2 minutes (extension), and a final extension
for 7 minutes at 68°C. With these conditions, the number
of cycles was selected on the basis of preliminary data that
indicated that the 28th cycle fell within the middle of the
exponential amplification range of the PCR assay for
GAPDH and the 30th cycle for eNOS primer sets (data not
shown). The RT-PCR products were separated with elec-
trophoresis on 2% agarose gel, and visualized with ethidium
bromide staining. The PCR product size was 341 base pairs
for eNOS and 240 base pairs for GAPDH. After measuring
band density, semiquantitative analysis was performed, and
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the data were presented as the ratio of eNOS and GAPHD
band density. Gels were analyzed with the Alpha Imager gel
documentation system and analysis software (Alpha Inno-
tech, San Leandro, Calif).
Western blot. Protein was isolated from endothelial
cells with Tri-Reagent according to the manufacturer’s
instructions. Protein isolated from two rings in the same
group was resuspended in 15 L of 10 M urea and heated
for 2 minutes at 100°C. Protein concentration was deter-
mined with the Bradford protein assay with bovine serum
albumin as standard. The same amount of endothelial
protein (6 g) from two vessel rings was resolved with
one-dimensional sodium dodecylsulphate (SDS) polyacryl-
amide gel electrophoresis (10% polyacrylamide) for approx-
imately 1 hour at 150 V. Subsequently the gels were
equilibrated in transfer buffer (48 mmol/L Tris, 39
mmol/L glycine, 0.03% SDS, 20% methanol), and the
proteins were electrophoretically transferred to nitrocellu-
lose filters overnight at 30 V. Filters were blocked with 5%
nonfat dried milk in TBS with 0.05% Tween 20 for 1 hour
at room temperature. eNOS was detected with a mouse
anti-human monoclonal antibody diluted 1:1000, and
-actin was detected with a mouse anti-human monoclonal
antibody diluted 1:10,000. eNOS and -actin primary
antibodies were detected with horseradish peroxidase–
conjugated goat anti-mouse immunoglobulin G secondary
antibodies diluted 1:2000. Blots were developed with en-
hanced chemiluminescence and analyzed with the Alpha
Imager gel documentation system and analysis software
(Alpha Innotech).
Immunohistochemistry. After the experiments, pig
coronary artery rings were fixed in 10% neutral buffered
formalin overnight, then transferred to 70% alcohol. The
specimens were dehydrated with sequentially increased
concentrations of ethanol followed by xylene, and embed-
ded in paraffin. Five-micrometer cross-sections were cut
and stained with hematoxylin-eosin and subjected to im-
munohistochemistry for eNOS with the avidin-biotin com-
plex immunoperoxidase procedure (LSAB kit; Dako), as
described.21,22 A monoclonal antibody (1:2000 dilution)
against human eNOS (BD Bioscience/Pharmingen) was
used. Two investigators examined all slides from each vessel
or ring, and representative slides were photographed.
Statistical analysis. Data from the various groups
were compared with an unpaired Student t test (two-
tailed). P  .05 was considered statistically significant.
Values are reported as mean  SEM.
RESULTS
Tat protein reduces endothelium-dependent vaso-
relaxation. The effect of Tat protein on pig coronary
artery ring (n  6) contractility is shown in Fig 1, A.
Maximum vessel tension after challenge with TxA2 analog
U46619 (107 mol/L) demonstrated no significant differ-
ences between control and Tat-treated groups (P 	 .05).
The control segments contracted 105.2  27.7 mN in
response to 107 mol/L TxA2 analog U46619, and vessels
treated with 107, 109, and 1011 mol/L of Tat protein
contracted 91.7 24.1, 97.05 29.6, and 120.89 18.9
mN, respectively (Fig 1, A). By contrast, Tat treatment
significantly decreased endothelium-dependent vasorelax-
ation in response to bradykinin in precontracted vessels
(Fig 1, B). At 107 mol/L of bradykinin challenge, control
vessels relaxed by 69.55  7.93%, whereas vessels treated
with 1011, 109, and 107 mol/L of Tat protein relaxed
61.35  9.73, 51.74  9.42, and 37.27  4.21%, respec-
tively. These values corresponded to 11.78%, 25.61%, and
46.41% reduction in endothelium-dependent vasorelax-
ation in vessels treated with 1011, 109, and 107 mol/L
of Tat protein, respectively, as compared with controls (P
Fig 1. Effect of HIV Tat protein on vasomotor activity of porcine
coronary arteries. Pig coronary artery rings (n  6) were cultured
as controls or treated with Tat protein (107, 109, 1011 mol/L)
for 24 hours. Subsequently contraction and relaxation were tested
with a myograph isometric tension apparatus. A, Contraction of
vessel rings in response to thromboxane A2 analog U46619 (10
7
mol/L) shows no significant difference between control and
treated groups (P 	 .05). B, Endothelium-dependent vasorelax-
ation of the precontracted vessel rings in response to bradykinin
(107 and 106 mol/L) shows significant reduction in Tat pro-
tein–treated group compared with control group (*P  .05).
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.05). Five groups of coronary artery rings were also tested
with the myography system to determine changes in vaso-
motor function resulting from exposure to Tat protein and
anti-Tat antibody plus Tat protein (Fig 2). Anti-Tat anti-
body was used to demonstrate that Tat protein was a
specific cause for the observed changes. Again, Tat pro-
tein (107 mol/L) significantly decreased endothelium-
dependent vasorelaxation by 40.77% and 26.13% in re-
sponse to bradykinin 108 and 107 mol/L, respectively,
but anti-Tat antibody completely blocked this effect of Tat
protein (Fig 2). Tat protein or anti-Tat antibody plus Tat
protein treatment did not affect endothelium-independent
maximal relaxation in response to a single high dose of
sodium nitroprusside (105 mol/L; data not shown). Thus
Tat protein specifically impaired endothelium-dependent
vasorelaxation, but did not affect smooth muscle cell func-
tion in pig coronary artery rings.
Tat protein reduces eNOS mRNA expression in
endothelial cells. To determine a possible reason for de-
creased endothelium-dependent relaxation seen in the
functional contraction and vasorelaxation assays, RT-PCR
was performed on endothelial cells removed from vessels
from each group after the functional assay (Fig 3, A). The
eNOS/GAPDH ratio was 0.6345  0.17 for the control
group, 0.1723 0.067 for the Tat protein–treated group,
and 0.529  0.099 for the anti-Tat antibody plus Tat
protein–treated group (Fig 3, B). These data represent a
significant reduction in eNOS mRNA production in Tat-
treated vessels compared with controls (P  .03). How-
ever, there was no difference in eNOS/GAPDH ratio
Fig 2. Effects of HIV Tat protein (107) and anti-Tat antibody
plus Tat protein on endothelium of porcine coronary arteries. Pig
coronary artery rings (n  5) were cultured as controls or treated
with Tat protein (107 mol/L) and anti-Tat antibody plus Tat
protein for 24 hours. A, Contraction of vessel rings in response to
thromboxane A2 analog U46619 (10
7 mol/L) shows no signif-
icant difference between control and treated groups (P 	 .05). B,
Endothelium-dependent vasorelaxation of precontracted vessel
rings in response to bradykinin (108, 107, and 106 mol/L)
shows significant reduction in Tat protein–treated group com-
pared with control group or anti-Tat antibody plus Tat protein–
treated group (*P  .05).
Fig 3. Effects of Tat protein and anti-Tat antibody plus Tat
protein on eNOS mRNA expression in porcine coronary arteries.
Endothelial cells were isolated from control or treated pig coronary
artery rings (n  11). eNOS mRNA levels were determined with
reverse transcriptase polymerase chain reaction and band density
analysis. A, Representative 2% agarose gel electrophoresis shows
reduced eNOS band density in Tat protein–treated group com-
pared with controls and anti-Tat antibody plus Tat protein–treated
vessels. B, eNOS/GAPDH band density ratio was significantly
reduced in Tat protein–treated vessels compared with controls (*P
 .05). However, anti-Tat antibody plus Tat protein–treated
group did not show any difference in mRNA levels compared with
controls (P 	 .05).
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between anti-Tat antibody plus Tat protein treatment and
control groups.
Tat protein reduces eNOS protein expression.
eNOS protein levels were determined with Western blot
analysis. Consistent with eNOS mRNA data, Tat protein–
treated vessels exhibited substantially less density of eNOS
protein bands compared with controls. These data were
analyzed with internal loading controls of -actin (Fig 4).
Furthermore, immunohistochemical staining was also used
to detect eNOS expression in pig coronary artery ring tissue
(Fig 5). Control vessels showed a strong positive staining
pattern of eNOS on the endothelial layer of the vessel walls.
However, Tat protein–treated vessels showed very light
staining for eNOS, while anti-Tat antibody plus Tat pro-
tein–treated vessels demonstrated a staining pattern similar
to that of controls.
DISCUSSION
Although extensive clinical investigations have indi-
cated that atherosclerosis is accelerated in patients with
HIV, the cellular and molecular mechanisms of HIV- me-
diated vascular pathogenesis are not fully understood. The
vascular endothelium is composed of a monolayer of endo-
thelial cells that line the vascular lumen. Endothelial cells
have vital functions in regulating vascular tone, smooth
muscle cell proliferation, coagulation and fibrinolysis, per-
meability, and blood cell adhesion and migration. A key
regulatory system of the endothelium involves nitric oxide
(NO), which acts as an endothelium-derived relaxing factor
for vascular smooth muscle in response to a variety of
stimuli, such as flow changes and certain drugs.21,22 The
release of NO induces vasodilation and regulates vascular
tone. NO not only acts as a vasodilator, but also has
inhibitory effects on the growth of smooth muscle cells and
the adhesion and aggregation of platelets. Impairment of
endothelium-dependent vasodilation appears to be a sensi-
tive indicator of endothelial dysfunction and the process of
atherosclerosis.23 It also has an important role in dynamic
plaque behavior in the coronary circulation.24 Endothelial
injury or dysfunction could significantly contribute to
pathogenesis of vascular disease in HIV-infected patients.
We used myography system to study the effect of Tat
protein on vasomotor functions in pig coronary arteries.
The results demonstrate that HIV Tat protein causes sig-
nificant reduction in endothelium-dependent relaxation in
porcine coronary artery rings incubated for 24 hours with
Fig 4. Effects of Tat protein on eNOS protein expression in
porcine coronary arteries. eNOS protein levels in endothelial cells
isolated from pig coronary artery rings were determined with
Western blot and band density analysis. Representative Western
blot film shows a lighter band of eNOS in Tat protein–treated
vessels compared with controls. eNOS protein was 141 KDa;
-actin was 42 KDa.
Fig 5. Immunoreactivity of eNOS in porcine coronary arteries.
Pig coronary artery rings were cultured as controls or treated with
Tat protein or anti-Tat antibody plus Tat protein for 24 hours,
then subjected to immunostaining for eNOS. Dark brown repre-
sents positive staining for eNOS. A, Control vessel rings show dark
staining of eNOS on endothelial cells. B, Tat protein–treated vessel
rings show markedly reduced eNOS staining. C, Anti-Tat antibody
plus Tat protein–treated vessel rings show dark staining of eNOS
on endothelial cells, as control vessel rings.
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Tat protein. Tat (107 mol/L) reduced vasorelaxation by
52.78% and 46.41%, respectively, in response to bradykinin
108 and 107 mol/L (Fig 1, B). In a separate experiment,
Tat (107 mol/L) reduced vasorelaxation by 40.77% and
26.13%, respectively, in response to bradykinin 108 and
107 mol/L (Fig 2, B). Thus we see some difference
between the two groups, which may be due to individual
variability of porcine hearts and experimental conditions.
These two groups of experiments were performed sepa-
rately, with their own controls. All demonstrated statistical
significance in comparison of pig vessels versus control
vessels. Thus the data support the conclusion that HIV Tat
significantly impairs endothelium-dependent vasorelax-
ation. Bradykinin causes endothelium-dependent vasore-
laxation. Sodium nitroprusside causes endothelium-inde-
pendent vasorelaxation. It releases NO, which directly acts
on smooth muscle cells. Smooth muscle function can be
directly determined with contraction and endothelium-
independent relaxation. In this study, Tat treatment did
not produce significant differences in contraction and en-
dothelium-independent relaxation of the artery rings in
response to a single relatively large dose of U46619 and
sodium nitroprusside, respectively. The results of this study
may explain in part the higher incidence of vascular disease
in HIV-infected patients, because endothelial dysfunction
is considered an event in the progression of atherogenesis.
To our knowledge, this is the first report to show an
independent effect of Tat protein on endothelium-
dependent vasorelaxation. However, nonspecific antibody
was not included as another negative control, although no
antibody was used as a negative control. This could be a
limitation of this study. Further investigation of the role of
HIV Tat in endothelial cell function, gene expression, and
NO production, including cell cultures and more stringent
controls, are warranted.
Endothelium-dependent vasorelaxation is an impor-
tant normal endothelial cell function. Impairment of this
function has been linked to development and progression
of atherosclerosis25. NO is the most important endotheli-
um-derived relaxation factor. Its production increases in
response to stimuli that cause activation of constitutive
eNOS. Thus agonists such as bradykinin induce vasorelax-
ation by engaging specific endothelial cell receptors that
stimulate production of NO and other vasodilator sub-
stances.26,27 In this study, with isometric tension analysis,
bradykinin-induced vasorelaxation was significantly re-
duced in pig coronary artery rings treated with Tat protein,
as compared with controls. In addition, Tat protein signif-
icantly decreased eNOS mRNA and protein expression in
endothelial cells of porcine coronary arteries. Furthermore,
histologic examination demonstrated reduced immunore-
activity of eNOS in Tat protein–treated pig coronary arter-
ies. There were no differences in vessel contractility in
response to TxA2 analog U46619 for coronary rings. There
was also no difference in endothelium-independent vasore-
laxation in response to sodium nitroprusside for coronary
rings between Tat protein–treated and control vessels.
These data suggest that smooth muscle function was not
affected by Tat protein treatment under the experimental
conditions.
Endothelial injury or dysfunction could significantly
contribute to pathogenesis of vascular disease in HIV-
infected patients. Capability of HIV infection in endothelial
cells is controversial. In certain types of endothelial cells or
at certain conditions, actual infection of endothelial cells
with HIV has been reported. Bobryshev et al28 reported
that there were significantly more HIV-1–infected den-
dritic cells in the atherosclerotic arteries than in nondis-
eased segments at immunohistochemical staining, and in-
dicated that accumulation of HIV-1 in dendritic cells in the
arterial wall may influence progression of atherosclerosis.
HIV Tat, the transactivator of viral transcription, acti-
vates mononuclear cells to secrete cytokines. Tat also acti-
vates endothelial cells to express inflammatory cytokines
and adhesion molecules, and contributes to angiogenesis
and development of Kaposi sarcoma.29,30 Tat caused apo-
ptosis of primary microvascular endothelial cells of lung
origin via a mechanism distinct from tumor necrosis factor
secretion or the Fas pathway.31,32 HIV Tat–mediated stim-
ulation of endothelial cell growth factor production is
linked to the underlying mechanism in HIV-infected pa-
tients with pulmonary hypertension.33 Alteration of endo-
thelial barrier function in HIV-infected patients may also
contribute to atherosclerosis and other vascular complica-
tions. Tat increases endothelial permeability in animal
models.34,35 After exposure of human umbilical vein endo-
thelial cells to Tat protein, surface expression of the adhe-
sion molecules intercellular adhesion molecule-1, vascular
cell adhesion molecule-1, and E-selectin rapidly in-
creased.16 Tat contributes to endothelial cell activation by
activating nuclear factor–
B (NF-
B),36 which has rele-
vance to atherosclerosis.37
Clinicians should be aware that HIV-infected patients
may be at higher risk for cardiovascular events compared
with HIV-negative persons. Conversely, HIV-infected pa-
tients may benefit as much as HIV-negative subjects from
interventions aimed at slowing of progression of atheroscle-
rosis, such as cessation of cigarette smoking or administra-
tion of lipid-lowering agents. Existing guidelines for man-
agement of dyslipidemia in the general population, such as
those of the National Cholesterol Education Program,
currently represent the basis for therapeutic recommenda-
tions in HIV-infected patients also.38,39
In summary, HIV Tat protein impairs endothelium-
dependent vasorelaxation in porcine coronary arteries in in
vitro experiments. eNOS downregulation and endothelial
injury may represent the mechanism by which HIV Tat
protein affects vascular disease in HIV-infected patients.
Our results suggest a functional and molecular relationship
between Tat protein and endothelial function, thereby
contributing further to understanding of the molecular
mechanisms of atherosclerosis.
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DISCUSSION
Dr Randolph Geary (Winston-Salem, NC). I would like to
commend the authors for bringing this to our attention and
reminding us of a serious and growing problem of premature
atherosclerosis in the HIV-AIDS population. I imagine we will all
be seeing a lot more of this in the future. I have always assumed that
the problem was related to dyslipidemia caused by protease inhib-
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